Drug-coated balloon treatment for lower extremity vascular disease intervention: An international positioning document

European Heart Journal

Volumn 37, Issue 14, 2016, Pages 1096-1103

  Cortese, Bernardo ^a   Granada, Juan F ^b   Scheller, Bruno ^c   Schneider, Peter A ^d   Tepe, Gunnar ^e   Scheinert, Dierk ^f   Garcia, Lawrence ^g   Stabile, Eugenio ^h   Alfonso, Fernando ⁱ   Ansel, Gary ^j   Zeller, Thomas ^k  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b Department of Medicine   (United States)

^c SAARLAND UNIVERSITY   (Germany)

^d KAISER PERMANENTE   (United States)

^e RodMed Klinikum   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j RIVERSIDE METHODIST HOSPITAL   (United States)

^k UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; DRUG IMPLANT; TUBULIN MODULATOR;

ATHERECTOMY; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DRUG COATED BALLOON; DRUG ELUTING STENT; DRUG MECHANISM; ECONOMIC EVALUATION; EVIDENCE BASED PRACTICE; GOLD STANDARD; HUMAN; LEG DISEASE; LOWER EXTREMITY VASCULAR DISEASE; NOTE; PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RESTENOTIC FEMORO POPLITEAL ARTERY DISEASE; VASCULAR DISEASE; CONSENSUS; DRUG IMPLANT; LOWER LIMB; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASES; PROCEDURES; RECURRENT DISEASE; VASCULARIZATION;

ANGIOPLASTY, BALLOON; CONSENSUS; DRUG IMPLANTS; HUMANS; LOWER EXTREMITY; PACLITAXEL; PERIPHERAL VASCULAR DISEASES; RECURRENCE; TUBULIN MODULATORS;

EID: 84966632829     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv204     Document Type: Note

References (55)

1. Cortese B, Berti S, Biondi-Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A, Silva PL, Sgueglia; Italian Society of Interventional Cardiology. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheter Cardiovasc Interv 2014; 83:427-435.
2. Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wohrle J, Jeger R, Levenson B, Mobius-Winkler S, Bruch L, Fischer D, Hengstenberg C, Porner T, Mathey D, Scheller B. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol 2013;102:785-797.
3. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619.
4. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Rother J, Sievert H, van Sambeek M, Zeller T, ESC Committee for Practice Guidelines. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2851-2906.
5. Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M, Biamino G, Schmidt A. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005;45:312-315.
6. Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol 2012; 161:4-12.
7. Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol 2014;11:13-23.
8. Speck U, Cremers B, Kelsch B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, Hanisch U, Bohm M, Scheller B. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?. Circ Cardiovasc Interv 2012;5:392-400.
9. Yeh TK, Lu Z, Wientjes MG, Au JL-S. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005;22:867-874.
10. Radke PW, Joner M, Joost A, Byrne RA, Hartwig S, Bayer G, Steigerwald K, Wittchow E. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention 2011;7:730-737.
11. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-814.
12. Stampfl U, Radeleff B, Sommer C, Stampfl S, Lopez-Benitez R, Thierjung H, Kurz P, Berger I, Richter GM. Paclitaxel-induced arterial wall toxicity and inflammation: part 2-long-Term tissue response in a minipig model. J Vasc Interv Radiol 2009; 20:1608-1616.
13. Cremers B, Milewski K, Clever YP, Aboodi MS, Biedermann M, Thim T, Kelsch B, Kaluza GL, Scheller B, Granada JF. Long-Term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis. Catheter Cardiovasc Interv 2012;80:603-610.
14. Levin AD, Vukmirovic N, Hwang C-W, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA 2004;101:9463-9467.
15. Balakrishnan B, Dooley JF, Kopia G, Edelman ER. Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J Control Release 2007; 123:100-108.
16. Axel DI, KunertW, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645.
17. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-699.
18. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118:1358-1365.
19. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. The LEVANT I trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014;7:10-19.
20. Werk M, Albrecht T, Meyer D-R, Ahmed MN, Behne A, Dietz U, Eschenbach G, Hartmann H, Lange C, Schnorr B, Stiepani H, Zoccai GB, Hanninen EL. Paclitaxelcoated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 2012;5: 831-840.
21. Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Novel paclitaxel releasing balloon in femoropopliteal lesions: 12-month evidence from the BIOLUX P-I randomized trial. JEVT 2015;22:14-21.
22. Micari A, Cioppa A, Vadala G, Castriota F, Liso A, Marchese A, Grattoni C, Pantaleo P, Cremonesi A, Rubino P, Biamino G. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv 2012; 5:331-338.
23. Cassese S, Byrne RA, Ott I, Ndrepepa G, Nerad M, Kastrati A, Fusaro M. Paclitaxelcoated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-Analysis of randomized trials. Circ Cardiovasc Interv 2012;5:582-589.
24. Tepe G, Zeller T, Schnorr B, Claussen CD, Beschorner U, Brechtel K, Scheller B, Speck U. High-grade, non-flow-limiting dissections do not negatively impact longterm outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther 2013;20:792-800.
25. Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, Speck U, Zeller T. Five-year follow-up data of the Thunder trial: angioplasty of femoropopliteal arteries with drug-coated balloons. JACC Cardiovasc Interv 2015;1: 102-108.
26. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR, for the IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015;131:495-502.
27. Bosiers M, Torsello G, Gissler H-M, Ruef J, Muller-Hulsbeck S, Jahnke T, Peeters P, Daenens K, Lammer J, SchroeH, Mathias K, Koppensteiner R, Vermassen F, Scheinert D. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther 2009;16:261-269.
28. Krankenberg H, Schluter M, Steinkamp HJ, Burgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tubler T, Zeller T. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 2007;116:285-292.
29. Dick P, Sabeti S, MlekuschW, Schlager O, Amighi J, Haumer M, Cejna M, Minar E, Schillinger M. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology 2008;248:297-302.
30. Stabile E, Virga V, Salemme L, Cioppa A, Ambrosini V, Sorropago G, Tesorio T, Cota L, Popusoi G, Pucciarelli A, Biamino G, Rubino P. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol 2012; 60:1739-1742.
31. Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, Tesorio T, Cota L, Popusoi G, Pucciarelli A, Esposito G, Trimarco B, Rubino P. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv 2014;7:411-415.
32. BlevinsWA, Schneider PA. Endovascular management of critical limb ischemia. Eur J Vasc Endovasc Surg 2010;39:756-761.
33. Ferraresi R, Centola M, Biondi-Zoccai G. Advances in below-The-knee drug-eluting balloons. J Cardiovasc Surg (Torino) 2012;53:205-213.
34. Soder HK, Manninen HI, Jaakkola P, Matsi PJ, Rasanen HT, Kaukanen E, Loponen P, Soimakallio S. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 2000;11: 1021-1031.
35. Schmidt A, Ulrich M, Winkler B, Klaeffling C, Bausback Y, Braunlich S, Botsios S, Kruse HJ, Varcoe RL, Kum S, Scheinert D. Angiographic patency and clinical outcome after balloon-Angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv 2010;76:1047-1054.
36. Baumann F, Willenberg T, Do D-D, Keo H-H, Baumgartner I, Diehm N. Endovascular revascularization of below-The-knee arteries: prospective short-Term angiographic and clinical follow-up. J Vasc Interv Radiol 2011;22:1665-1673.
37. Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M, Krankenberg H, Baumgartner I, Siablis D, Lammer J, Van Ransbeeck M, Qureshi AC, Stoll HP, ACHILLES Investigators. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 2012;60:2290-2295.
38. Romiti M, Albers M, Brochado-Neto FC, Durazzo AES, Pereira CAB, De Luccia N. Meta-Analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008;47:975-981.
39. Schmidt A, Piorkowski M, Werner M, Ulrich M, Bausback Y, Braunlich S, Ick H, Schuster J, Botsios S, Kruse HJ, Varcoe RL, Scheinert D. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol 2011;58:1105-1109.
40. Liistro F, Porto I, Angioli P, Grotti S, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G, Bolognese L. Drug-Eluting Balloon in peripherAl inTErvention for Below the Knee Angioplasty Evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation 2013;128:615-621.
41. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, Peeters P, Vermassen F, Landini M, IN.PACT DEEP Trial Investigators. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol 2014;64:1568-1576.
42. McKinsey JF, Zeller T, Rocha-Singh KJ, Jaff MR, Garcia LA, DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv 2014;7:923-933.
43. Sixt S, Carpio Cancino OG, Treszl A, Beschorner U, Macharzina R, Rastan A, Krankenberg H, Neumann FJ, Zeller T. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg 2013;58:682-686.
44. Cioppa A, Stabile E, Popusoi G, Salemme L, Cota L, Pucciarelli A, Ambrosini V, Sorropago G, Tesorio T, Agresta A, Biamino G, Rubino P. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: one-year single centre clinical results. Cardiovasc Revasc Med 2012;13:219-223.
45. Liistro F, Grotti S, Porto I, Angioli P, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G, Bolognese L. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv 2013;6:1295-1302.
46. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011;124:17-23.
47. Inglis SC, Lewsey JD, Lowe GDO, Jhund P, Gillies M, Stewart S, Capewell S, Macintyre K, McMurray JJ. Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: impact on general and mental health, quality of life and five-year mortality. Int J Cardiol 2013;167:2149-2155.
48. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1329-1340.
49. Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv 2014;84:546-554.
50. Diehm N, Schneider H. Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions. J Endovasc Ther 2013;20:819-825.
51. Kearns BC, Michaels JA, Stevenson MD, Thomas SM. Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. Br J Surg 2013;100: 1180-1188.
52. Cremers B, Schmitmeier S, Clever YP, Gershony G, Speck U, Scheller B. Inhibition of neo-intimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxelcoated scoring balloon catheter. Catheter Cardiovasc Interv 2014;84:1089-1098.
53. GrayWA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation 2010;121:2672-2680.
54. Fanelli F, Cannavale A, Boatta E, Corona M, Lucatelli P, Wlderk A, Cirelli C, Salvatori FM. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther 2012;19:571-580.
55. Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwalder U, Schwarz T, Noory E. Drug eluting balloons vs. drug eluting stents in long femoropopliteal lesions-A retrospective propensity score analysis. J Endovasc Therapy 2014;21:359-368.